Back to top

RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)

RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company today and set a price target of $51.00. According to Tip...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NewAmsterdam Pharma Company N.V. (NAMS)